Polymyxin B inhibits pro-inflammatory effects of E. coli outer membrane vesicles whilst increasing immune cell uptake

Bradley Whitehead1,2, Fabio Antennuci3, Anders T Boysen4,5

  • 1Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark. bradley@clin.au.dk.

Insights

Polymyxin B (PMB) antibiotic neutralizes bacterial outer membrane vesicles (OMVs) by masking their lipopolysaccharide (LPS). This process enhances immune cell uptake of OMVs while reducing inflammatory cytokine production.

Area of Science:

  • Microbiology
  • Immunology
  • Pharmacology

Background:

  • Polymyxin B (PMB) is a peptide antibiotic targeting bacterial lipopolysaccharide (LPS).
  • Outer membrane vesicles (OMVs) can sequester PMB, potentially protecting bacteria.
  • The interaction between PMB and OMVs and its effect on immune responses are not fully understood.

Purpose of the Study:

  • To investigate how PMB affects the immune-stimulatory properties of Escherichia coli OMVs.
  • To determine if PMB modulates the uptake of OMVs by human immune cells.

Main Methods:

  • Assessing PMB's ability to neutralize immune-stimulatory properties of OMVs.
  • Modulating the uptake of OMVs in human immune cells with PMB.
  • Measuring TNF and IL-1β production.

Main Results:

  • PMB increases the uptake of E. coli OMVs by human immune cells.
  • PMB inhibits the production of inflammatory cytokines TNF and IL-1β in response to OMVs.
  • LPS masking by PMB is suggested as a mechanism for altered OMV-host interaction.

Conclusions:

  • PMB exhibits a novel role in neutralizing OMVs.
  • PMB enhances immune cell uptake of OMVs.
  • PMB may serve as a therapeutic agent to modulate OMV-induced inflammation.